Topics

Human medicines European public assessment report (EPAR): DuoResp Spiromax, budesonide / formoterol, Pulmonary Disease, Chronic Obstructive,Asthma, Date of authorisation: 28/04/2014, Revision: 8, Status: Authorised

10:36 EST 7 Nov 2019 | European Medicines Agency

Human medicines European public assessment report (EPAR): DuoResp Spiromax, budesonide / formoterol, Pulmonary Disease, Chronic Obstructive,Asthma, Date of authorisation: 28/04/2014, Revision: 8, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): DuoResp Spiromax, budesonide / formoterol, Pulmonary Disease, Chronic Obstructive,Asthma, Date of authorisation: 28/04/2014, Revision: 8, Status: Authorised

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): DuoResp Spiromax, budesonide / formoterol, Pulmonary Disease, Chronic Obstructive,Asthma, Date of authorisation: 28/04/2014, Revision: 8, Status: Authorised"

Quick Search

Relevant Topic

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...